Breast cancer in Western Australia: clinical practice and clinical guidelines

被引:19
|
作者
McEvoy, SP
Ingram, DM
Byrne, MJ
Joseph, DJ
Dewar, J
Trotter, J
Harper, C
Haworth, C
Harvey, JM
Sterrett, GF
Jamrozik, K
Fritschi, L
机构
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
[2] Royal Perth Hosp, Breast Ctr, Perth, WA, Australia
[3] Perth Radiat Oncol Ctr, Perth, WA, Australia
[4] Pathctr, Perth, WA, Australia
[5] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, London, England
关键词
D O I
10.5694/j.1326-5377.2004.tb06294.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To review changes in patterns of care for women with early invasive breast cancer in Western Australia from 1989 to 1999, and compare management with recommendations in the 1995 National Health and Medical Research Council guidelines. Design and setting: Population-based surveys of all cases listed in the Western Australian Cancer Registry and Western Australian Hospital Morbidity Data System. Main outcome measures: Congruence of care with guidelines. Results: Data were available for 1649 women with early invasive breast cancer (categories pT1 or pT2; pN0 or pN1; and M0). In 1999, 96% had a preoperative diagnosis by fine-needle aspiration or core biopsy (compared with 66% in 1989), with a synoptic pathology report on 95%. Breast-conserving surgery was used for 66% of women with mammographically detected tumours (v 35% in 1989) and 46% of those with clinically detected tumours (v 28% in 1989), with radiotherapy to the conserved breast in 90% of these cases (83% in 1989). Adjuvant chemotherapy was given to 92% of premenopausal women with node-positive disease and 63% with poor-prognosis node-negative tumours (v 78% and 14%, respectively, in 1989). Among postmenopausal women with receptor-positive tumours, tamoxifen was prescribed for 91% of those with positive nodes (85% in 1989) and 79% of those with negative nodes (30% in 1989). Among postmenopausal women with receptor-negative tumours, chemotherapy was prescribed for 70% with positive nodes (v 33%) and 58% with negative nodes (v none). Conclusions: Patterns of management of women with early invasive breast cancer in Western Australia during the 1990s changed significantly in all respects toward those recommended in the 1995 guidelines.
引用
收藏
页码:305 / +
页数:6
相关论文
共 50 条
  • [31] Clinical practice guidelines for the diagnosis and treatment of inflammatory breast cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2022
    Ma, Li
    Zhang, Yanshou
    Tang, Tiantian
    Zhang, Xiangmei
    Liu, Yunjiang
    CHINESE MEDICAL JOURNAL, 2023, 136 (16) : 1894 - 1896
  • [32] Clinical practice guidelines for pregnancy-associated breast cancer: Chinese society of breast surgery (CSBrS) practice guidelines 2021
    Qing Chen
    Yi-Ran Qiu
    Ming-Di Zhang
    Wei Zhu
    Wei-Rong Gu
    Ke-Jin Wu
    中华医学杂志(英文版), 2021, 134 (20) : 2395 - 2397
  • [33] Clinical practice guidelines for modified radical mastectomy of breast cancer: Chinese Society of Breast Surgery (CSBrs) practice guidelines 2021
    Jiao De-Chuang
    Zhu Jiu-Jun
    Qin Li
    Guo Xu-Hui
    Zhao Ya-Jie
    Chen Xiu-Chun
    Wang Cheng-Zheng
    Lu Zhen-Duo
    Li Lian-Fang
    Cui Shu-De
    Liu Zhen-Zhen
    Chinese Society of Breast Surgery
    中华医学杂志(英文版), 2021, 134 (08) : 895 - 897
  • [34] Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021
    Liu Miao
    Wang Chao-Bin
    Xie Fei
    Peng Yuan
    Wang Shu
    Chinese Society of Breast Surgery
    中华医学杂志(英文版), 2021, 134 (09) : 1009 - 1013
  • [35] The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines
    Buettner, Stefan
    Koerkamp, Bas Groot
    HEPATOBILIARY SURGERY AND NUTRITION, 2023, 12 (02) : 244 - 247
  • [36] The Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition
    Yoshimura, Michio
    Yamauchi, Chikako
    Sanuki, Naoko
    Hamamoto, Yasushi
    Hirata, Kimiko
    Kawamori, Jiro
    Kawamura, Mariko
    Ogita, Mami
    Yamamoto, Yutaka
    Iwata, Hiroji
    Saji, Shigehira
    BREAST CANCER, 2024, 31 (03) : 347 - 357
  • [37] The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition
    Inokuchi, Masafumi
    Kutomi, Goro
    Kijima, Yuko
    Sakai, Takehiko
    Sawaki, Masataka
    Shien, Tadahiko
    Hanamura, Noriko
    Yano, Kenji
    Wada, Noriaki
    Saji, Shigehira
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (01) : 4 - 8
  • [38] The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
    Uematsu, Takayoshi
    Nakashima, Kazutaka
    Kikuchi, Mari
    Kubota, Kazunori
    Suzuki, Akihiko
    Nakano, Shogo
    Hirokaga, Kouichi
    Yamaguchi, Ken
    Saji, Shigehira
    Iwata, Hiroji
    BREAST CANCER, 2020, 27 (01) : 17 - 24
  • [39] The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition
    Naoko Honma
    Masayuki Yoshida
    Keiichi Kinowaki
    Rie Horii
    Yuka Katsurada
    Yuya Murata
    Ai Shimizu
    Yuko Tanabe
    Chikako Yamauchi
    Yutaka Yamamoto
    Hiroji Iwata
    Shigehira Saji
    Breast Cancer, 2024, 31 : 8 - 15
  • [40] The Japanese Breast Cancer Society clinical practice guidelines for epidemiology and prevention of breast cancer, 2022 edition
    Kawai, Masaaki
    Ohtani, Shoichiro
    Iwasaki, Motoki
    Yamamoto, Seiichiro
    Takamatsu, Kiyoshi
    Okamura, Hitoshi
    Arai, Masami
    Nomura, Tsunehisa
    Ozaki, Shinji
    Shibata, Ken-ichi
    Akabane, Ayaka
    Motoi, Fuyuhiko
    Yamauchi, Chikako
    Yamamoto, Yutaka
    Iwata, Hiroji
    Saji, Shigehira
    BREAST CANCER, 2024, 31 (02) : 166 - 178